19-362 - Safety and Pharmacokinetics Study of MK-5890 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)Status: open
A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors
Treatment for Advanced Solid Tumors
If you have questions about this trial or are interested in participating, please contact this Clinical Trial’s Coordinator by email at email@example.com.
The purpose of this study is to assess the safety and pharmacokinetics of MK-5890 when administered alone and in combination with pembrolizumab (MK-3475) in adults with advanced solid tumors. The initial course of MK-5890 monotherapy or MK-5890 plus pembrolizumab combination therapy will be for up to 35 administrations (approximately 2 years). The safety and pharmacokinetics of MK-5890 when administered with pembrolizumab, pemetrexed and carboplatin will also be assessed in adults with non-squamous non-small cell lung cancer (NSCLC).
SponsorsThis trial is sponsored by University of Chicago.
Providers Associated With This Trial
- Jennifer M. Scalici, M.D.Gynecologic OncologistChief of Gynecologic Oncology Service; Professor of Interdisciplinary Clinical Oncology; Director of Gynecologic Oncology Research Laboratory
- Nathaniel Jones, M.D.Gynecologic OncologistAssistant Professor of Interdisciplinary Clinical Oncology
- Jennifer Young Pierce, M.D., M.P.H., F.A.C.O.G.Gynecologic OncologistLeader of Cancer Control and Prevention; Program Director for the Gynecologic Oncology Fellowship; Professor of Interdisciplinary Clinical Oncology
- Donna Lynn Dyess, M.D., F.A.C.S.Breast/Endocrine SurgeonProfessor of Surgery